Segui
Antonio Scalfari
Antonio Scalfari
Consultant Neurologist, honorary clinical senior lecturer, Imperial College London
Email verificata su imperial.ac.uk - Home page
Titolo
Citata da
Citata da
Anno
The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability
A Scalfari, A Neuhaus, A Degenhardt, GP Rice, PA Muraro, M Daumer, ...
Brain 133 (7), 1914-1929, 2010
8622010
Abnormal associative plasticity of the human motor cortex in writer’s cramp
A Quartarone, S Bagnato, V Rizzo, HR Siebner, V Dattola, A Scalfari, ...
Brain 126 (12), 2586-2596, 2003
4902003
Onset of secondary progressive phase and long-term evolution of multiple sclerosis
A Scalfari, A Neuhaus, M Daumer, PA Muraro, GC Ebers
Journal of Neurology, Neurosurgery & Psychiatry 85 (1), 67-75, 2014
3832014
Mortality in patients with multiple sclerosis
A Scalfari, V Knappertz, G Cutter, DS Goodin, R Ashton, GC Ebers
Neurology 81 (2), 184-192, 2013
3702013
Age and disability accumulation in multiple sclerosis
A Scalfari, A Neuhaus, M Daumer, GC Ebers, PA Muraro
Neurology 77 (13), 1246-1252, 2011
3042011
Clinical prognostic factors in multiple sclerosis: a natural history review
A Degenhardt, SV Ramagopalan, A Scalfari, GC Ebers
Nature Reviews Neurology 5 (12), 672-682, 2009
2202009
Smouldering multiple sclerosis: the ‘real MS’
G Giovannoni, V Popescu, J Wuerfel, K Hellwig, E Iacobaeus, MB Jensen, ...
Therapeutic advances in neurological disorders 15, 17562864211066751, 2022
1812022
Early relapses, onset of progression, and late outcome in multiple sclerosis
A Scalfari, A Neuhaus, M Daumer, GC DeLuca, PA Muraro, GC Ebers
JAMA neurology 70 (2), 214-222, 2013
1382013
The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis
A Scalfari, C Romualdi, RS Nicholas, M Mattoscio, R Magliozzi, A Morra, ...
Neurology 90 (24), e2107-e2118, 2018
1292018
The relationship of age with the clinical phenotype in multiple sclerosis
A Scalfari, C Lederer, M Daumer, R Nicholas, GC Ebers, PA Muraro
Multiple Sclerosis Journal 22 (13), 1750-1758, 2016
862016
Treatment with disease‐modifying drugs for people with a first clinical attack suggestive of multiple sclerosis
G Filippini, C Del Giovane, M Clerico, O Beiki, M Mattoscio, F Piazza, ...
Cochrane database of systematic reviews, 2017
752017
Regional distribution and evolution of gray matter damage in different populations of multiple sclerosis patients
M Calabrese, R Reynolds, R Magliozzi, M Castellaro, A Morra, A Scalfari, ...
PloS one 10 (8), e0135428, 2015
702015
The CSF profile linked to cortical damage predicts multiple sclerosis activity
R Magliozzi, A Scalfari, AI Pisani, S Ziccardi, D Marastoni, FB Pizzini, ...
Annals of neurology 88 (3), 562-573, 2020
642020
Autologous hematopoietic stem cell transplantation in active multiple sclerosis: a real-world case series
RS Nicholas, EE Rhone, A Mariottini, E Silber, O Malik, V Singh-Curry, ...
Neurology 97 (9), e890-e901, 2021
362021
AW eb‐based tool for personalized prediction of long‐term disease course in patients with multiple sclerosis
I Galea, C Lederer, A Neuhaus, PA Muraro, A Scalfari, N Koch‐Henriksen, ...
European journal of neurology 20 (7), 1107-1109, 2013
332013
Acute inflammatory diseases of the central nervous system after SARS-CoV-2 vaccination
AG Francis, K Elhadd, V Camera, M Ferreira dos Santos, C Rocchi, ...
Neurology: Neuroimmunology & Neuroinflammation 10 (1), e200063, 2022
322022
Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
S Pfeuffer, T Ruck, R Pul, L Rolfes, C Korsukewitz, M Pawlitzki, ...
Journal of Neurology, Neurosurgery & Psychiatry 92 (9), 1007-1013, 2021
302021
Pharmacological approaches to the management of secondary progressive multiple sclerosis
A Nandoskar, J Raffel, AS Scalfari, T Friede, RS Nicholas
Drugs 77, 885-910, 2017
262017
A novel prognostic score to assess the risk of progression in relapsing− remitting multiple sclerosis patients
AI Pisani, A Scalfari, F Crescenzo, C Romualdi, M Calabrese
European journal of neurology 28 (8), 2503-2512, 2021
252021
MS progression is predominantly driven by age-related mechanisms–YES
A Scalfari
Multiple Sclerosis Journal 25 (7), 902-904, 2019
212019
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20